Search

Displaying results 3101 - 3110 of 4859 in total
  1. Drug

    (S)-acetoin

    go.drugbank.com/drugs/DB02788
    Experimental

    It is a component of the butanediol cycle in microorganisms. In mammals it is oxidized to carbon dioxide.

  2. Drug

    Nimodipine

    go.drugbank.com/drugs/DB00393
    ApprovedInvestigational

    It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation.

  3. Drug

    Zafirlukast

    go.drugbank.com/drugs/DB00549
    Approved

    It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), which is usually taken just once daily.

  4. Drug

    Berahyaluronidase alfa

    go.drugbank.com/drugs/DB22790
    ApprovedInvestigational

    It is used in a fixed-dose combination with [pembrolizumab] for subcutaneous injection.

  5. Drug

    Alglucerase

    go.drugbank.com/drugs/DB00088
    ApprovedWithdrawn

    Alglucerase was first approved by the FDA in 1991;[A254816] however, it was later discontinued from the market.

  6. Drug

    Metocurine iodide

    go.drugbank.com/drugs/DB00416
    ApprovedWithdrawn

    It is used as an anesthesia adjunct to induce skeletal muscle relaxation and to reduce the intensity of muscle contractions in convulsive therapy Metocurine iodide has a moderate risk of inducing histamine

  7. Drug

    Nitrofurantoin

    go.drugbank.com/drugs/DB00698
    ApprovedInvestigationalVet approved

    [A179824] This drug is more resistant to the development of bacterial resistance because it acts on many targets at once.

  8. Drug

    Glyburide

    go.drugbank.com/drugs/DB01016
    ApprovedInvestigational

    [L8123] It is typically given to patients who cannot be managed with the standard first line therapy, [metformin].

  9. Drug

    Brensocatib

    go.drugbank.com/drugs/DB15638
    Approved

    [A274348,A274343] It reduces exacerbations and slows lung function decline, offering a targeted approach to managing NCFB.

  10. Drug

    Human papillomavirus type 33 L1 capsid protein antigen

    go.drugbank.com/drugs/DB10311
    ApprovedInvestigational

    It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) type 33.